April 19, 2018 / 4:13 PM / a month ago

BRIEF-Theranexus Announces First European Authorization For Clinical Study Of Phase 2 With Thn 102 In Parkinson's Disease

April 19 (Reuters) - THERANEXUS SA:

* ANNOUNCES FIRST EUROPEAN AUTHORIZATION FOR CLINICAL STUDY OF PHASE 2 WITH THN 102 IN PARKINSON’S DISEASE

* FIRST GREEN LIGHT FOR LAUNCH OF MULTICENTRIC INTERNATIONAL STUDY PHASE 2 Source text : bit.ly/2EXTIJP Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below